Equity
€1.1m ▼ 5.7%
ROXASS paid out €495,000 in dividends. That is 116% of the 2025 profit.
ROXASS
Lifetime
19 annual accounts with figures on one time axispeak €547,394 (2025)
€547,394▲ 32.8%
lowest -€144,231 (2018)
€426,632▲ 280%
peak €1.2m (2024)
€1.1m▼ 5.7%
€483,966▲ 9.0%
peak 1 FTE (2018)
-not published
Board1 name since 2018
1 director
Documentsfilings and deeds
30-09-202661 days late
2025micro format
Gross margin from €412,261 to €547,394Result from €112,182 to €426,632Dividend €495,000Cash from €14,085 to €367
Key points
from the 2025 annual accountsResult
€426,632 ▲ 280%
The result rose in 2025 from €112,182 to €426,632.
Turnover
≈ €820,000 estimated
The micro format states no turnover.
Liquidity
9.80 was 16.81 in 2024
Short-term debts rose from €96,146 to €162,470.
Filings
19 annual accounts 61 days
Latest accounts filed late: after the legal deadline.
Position in the sector
€426,632
Higher net result than 95% of companies in human health. Sector median €59,563 · 21,309 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 34,721 companies had the same profile as ROXASS has now. Each dot stands for 87 companies, two years later.
95.3%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 34,721 companies, not a prediction for ROXASS. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Change of role: , from manager to director
“L’achat, la vente, l’échange d’immeubles, la constitution ou cession de droits réels immobiliers, la division…” (deed in French) · Legal-form conversion: from private limited company (pre-2019) to private limited company · Director discharge: · General meeting of 12-12-2023 · Gazette deed
Reappointment: (manager)
General meeting of 11-01-2018 · Gazette deed
First establishment
Merlostraat 138, Uccle
Incorporation
published on 14-02-2007 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| ROXASS Uccle | €1.6m | €547,394 | 69.9% | - |
| DR.A.KELLES Brussels | €1.7m | €554,983 | 95.9% | 2.1 |
| DOKTER ERIC JOLIE Brussels | €1.7m | €592,018 | 95.6% | - |
| DR. BERNARD CAMBIER Sint-Martens-Latem | €1.5m | €543,020 | 46.3% | 2.3 |
| Dr. Ph. Chappel Edegem | €1.7m | €538,341 | 97.4% | - |
| GHEERARDYN Mons | €1.6m | €514,167 | 41.3% | - |
| DOKTER OLIVIER VERBORGT Antwerp | €1.5m | €541,374 | 94.5% | 0 |
These companies have the same main activity as ROXASS: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €1.5m and €1.7m, founded between 2004 and 2007.
Official details
Source: KBO- Status
- Active since 06-02-2007Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.260.010.8191180 Uccle, since 01-01-2017
- Financial year end
- 31 December
- Peppol
- Not found in the Peppol Directory
Insights on ROXASS
ROXASS files the micro format. That format states no turnover. The gross margin rose from €116,728 in 2007 to €547,394 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about ROXASS
- What is the company number of ROXASS?
- The company number of ROXASS is 0887.031.346. The VAT number is the same number with BE in front: BE 0887.031.346.
- Where is ROXASS based?
- The registered office is at Merlostraat 138, 1180 Uccle.Company details
- What does ROXASS do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of ROXASS?
- ROXASS is a private limited company (BV).
- When was ROXASS founded?
- ROXASS was founded on 06-02-2007.
- Is ROXASS still active?
- Yes, ROXASS is an active enterprise in the KBO register.
- How many employees does ROXASS have?
- ROXASS had an average of 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of ROXASS?
- The turnover in financial year 2025 is ≈ €820,000. This figure is estimated from the gross margin of €547,394 and 31 comparable companies (NACE 86220). It probably lies between €730,000 and €1.1m.
- Is ROXASS profitable?
- In financial year 2025, ROXASS made a profit of €426,632.
- Where can I find the annual accounts of ROXASS?
- ROXASS filed 19 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of ROXASS due?
- ROXASS must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.